MacroGenics Inc (MGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $140.60M
Last updated: Nov 17, 2026 at 11:06 AM ET
MacroGenics Inc (MGNX) Stock Forecast
Analysts expect MacroGenics (MGNX) to earn -$1.56 per share in the fiscal year ending Dec 31, 2026, on revenue of $108.20M. Of 7 analysts, 3 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.43, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 43% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 2 | 28.6% |
| Hold | 4 | 57.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 16.3%.
- Fiscal year ending Dec 31, 2026
- -$1.56
- EPS consensus, revenue $108.20M
- Fiscal year ending Dec 31, 2027
- -$1.47
- EPS consensus, revenue $90.61M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.56 | -$3.20 to -$0.28 | 7 | $108.20M | $65.40M to $148.27M | 6 |
| Dec 31, 2027 | -$1.47 | -$1.70 to -$1.23 | 2 | $90.61M | $26.00M to $155.83M | 5 |
Quarterly Estimates
The EPS consensus falls from -$0.26 for the quarter ending Dec 31, 2026 to -$0.51 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.26 | -$0.48 to $0.33 | 9 | $36.86M | $16.86M to $76.65M | 8 |
| Mar 31, 2027 | -$0.51 | -$0.75 to -$0.30 | 3 | $8.25M | $1.50M to $15.00M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.67.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.56 | -$1.56 | -$1.56 | -$1.55 | -$0.67 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.47 | -$1.14 | -$1.41 | -$1.41 | -$1.41 | N/A |
| Quarter ending Mar 31, 2027 | -$0.51 | -$0.51 | -$0.51 | -$0.51 | -$0.38 | N/A |
Frequently Asked Questions About MGNX
What is the MGNX stock forecast?
Consensus analyst estimates put MacroGenics's EPS at -$1.56 for the fiscal year ending Dec 31, 2026, on revenue of $108.20M. The consensus rating from 7 analysts is Buy.
How do analysts rate MGNX stock?
Of 7 analysts covering MacroGenics, 1 rates it Strong Buy, 2 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MGNX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.56, with estimates from -$3.20 to -$0.28 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.47, with estimates from -$1.70 to -$1.23 from 2 analysts.
What revenue do analysts expect from MacroGenics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $108.20M, with estimates from $65.40M to $148.27M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $90.61M, with estimates from $26.00M to $155.83M.
How many analysts cover MGNX?
7 analysts rate MacroGenics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MGNX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts